HealthQuill Eli Lilly and Company
Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid tumours, for $2.5 billion in cash.
Drugs Health Medical

Eli Lilly to buy Scorpion Therapeutics’ cancer drug for $2.5 billion

Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid.

Read More
Eli Lilly and Company will invest $3 billion in the US to expand its manufacturing facility to meet a rise in demand for medicines in the areas of diabetes and obesity.
Uncategorized

Eli Lilly to expand US facility as demand soars for diabetes, obesity medicines

Eli Lilly and Company will invest $3 billion in the US to expand its manufacturing facility to meet a rise in demand for.

Read More
Eli Lilly and Company will build a $4.5 billion center for advanced manufacturing and drug development in Indiana to innovate new production methods.
Drugs Health Medical

Lilly to invest $4.5 billion to build Medicine Foundry in Indiana state, US

Eli Lilly and Company will build a $4.5 billion center for advanced manufacturing and drug development in Indiana to innovate new production methods.

Read More
Tirzepatide is an approved GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) treatment for chronic weight management, commercialised as Zepbound in the US and Mounjaro in some global markets outside the US.
Drugs Health Pharma

Eli Lilly’s Zepbound resolves sleep apnea in more than half of trial patients 

Tirzepatide, an obesity drug of  Eli Lilly and Company, has helped resolve moderate-to-severe obstructive sleep apnea in 52.% of adult patients in two.

Read More